On Monday, Shares of QUALCOMM, Inc. (NASDAQ:QCOM), lost -1.51% to $56.58.
Qualcomm Incorporated, declared that its partner, Qualcomm Life, Inc., is collaborating with Davita Healthcare Partners and P2Link to develop chronic care administration solutions powered by Qualcomm Life’s 2net™ Device Connectivity Platform and HealthyCircles™ Care Coordination Platform to enable continuous care, informed interventions and better administration of at-risk populations. The collaborations were declared at Qualcomm Life’s annual Connect 2015 ecosystem conference taking place on August 31 and September 1, 2015 in San Diego, California.
Davita HealthCare Partners, one of the largest medical groups and physician network operators, provides integrated care administration for about 830,000 patients, more than 600,000 of which live in California and represent diverse cultures, socioeconomic groups, ages, and health statuses. The company will integrate Qualcomm Life’s 2net Mobile and HealthyCircles technologies into a coordinated care program for patients with heart failure (HF). Patients will be equipped with a home blood pressure monitor, a weight scale, and a tablet powered by 2net Mobile to seamlessly collect and transmit the biometric data to the cloud. Patients will also leverage the HealthyCircles Platform to monitor the patient’s health status at home, receive relevant educational content, and targeted, proactive care administration interventions. The initial program will roll out in Q4 2015.
QUALCOMM Incorporated designs, develops, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, and the United States. The company operates through three segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Planned Initiatives (QSI).
Shares of Immunomedics, Inc. (NASDAQ:IMMU), remained flat at $2.16, during its last trading session.
Immunomedics, declared the issuance of U.S. Patent No. 9,107,960 for a new patent family “Antibody-SN-38 Immunoconjugates with a CL2A Linker.” Expiring in July 2033, the new patent concerns improved methods and compositions for preparing SN-38 conjugates of antibodies or antibody fragments using the Company’s proprietary antibody-drug linker, CL2A. The allowed claims cover the Company’s first-in-class antibody-drug conjugates (ADCs), sacituzumab govitecan and labetuzumab govitecan, presently being investigated as a therapy of solid cancers.
As stated by the Company’s outside clinical investigators at the 2015 annual meeting of the American Society of Clinical Oncology, both ADCs showed encouraging activity with manageable side effects in two separate mid-stage clinical studies in patients heavily-pretreated for their advanced metastatic solid cancers.
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company is developing Yttrium-90-labeled clivatuzumab tetraxetan, which is in Phase III registration study used for the treatment of pancreatic cancer.
Finally, Owens Corning (NYSE:OC), ended its last trade with 0.59% gain, and closed at $44.29.
From the exterior building envelope to the interior mechanical systems, Owens Corning is at the forefront of delivering building science-driven technology and innovation to the commercial building industry. The introduction of the all-new Owens Corning® ASJ Max FIBERGLAS™ Pipe Insulation brings additional depth to the extensive Owens Corning® pipe insulation solutions designed for hot and cold, concealed and exposed piping applications in commercial and industrial buildings.
“Owens Corning is committed to serving the commercial building market with solutions that deliver an outstanding fit for commercial pipe insulation needs,” said Todd Fister, Vice President Insulation Marketing, Owens Corning. “With the introduction of Owens Corning® ASJ Max FIBERGLAS™Pipe Insulation, contractors and mechanical engineers have the confidence of knowing we’ve got them covered with products that meet changing codes and complexities on recently’s jobs.”
Owens Corning, together with its auxiliaries, produces and sells glass fiber reinforcements and other materials for composite systems; and residential and commercial building materials worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
